Drugs that target amyloid beta proteins in the brain likely have no clinically meaningful positive effects, while increasing the risk of bleeding and swelling in the brain, a new Cochrane review has found.

Restoring both walking and sensation to patients with paraplegia is an ambitious goal—but a team of researchers from the Keck School of Medicine of USC, the University of California, Irvine (UCI) and the California Institute of Technology (Caltech) is now one step closer. With $8 million in funding from the highly competitive National Science Foundation CyberPhysical Systems program, the team is building a fully implantable brain-computer interface (BCI) that allows patients to use their thoughts to control wearable robotic legs, known as a robotic exoskeleton. The system is designed to help patients walk while also restoring the sensation of walking. In the first full test, the BCI was about 92% accurate at both reading step signals from the brain and delivering artificial walking sensation. Existing brain-computer interfaces that restore walking send signals in just one direction, from brain to device. The team’s early proof-of-concept study, done in a patient with epilepsy who had electrodes implanted as part of her medical care, shows it is possible to build a bidirectional, or two-way, system. During the demonstration, the patient sat on her hospital bed with the device by her side (future versions will be small enough to implant inside the body), while one of the researchers wore the robot exoskeleton. When the patient mimed taking a step, the device signaled the exoskeleton, sending the researcher on a walk around the intensive care unit. The system correctly detected brain signals indicating the intent to walk about 92% of the time. The demonstration helped the researchers earn an Investigational Device Exemption from the U.S. Food and Drug Administration, which allows them to test the device in a clinical trial for patients with paraplegia. They aim to implant electrodes for 30 days as a time, using that window to test and refine the system’s capabilities.

A landmark international clinical trial led by researchers at the Centre for Addiction and Mental Health (CAMH) and University of California San Diego School of Medicine, published in The Lancet Psychiatry, has found that magnetic seizure therapy (MST) is as effective as electroconvulsive therapy (ECT)—the current gold-standard treatment for severe, treatment-resistant depression—with significantly fewer cognitive side effects. The study is the first large-scale, randomized clinical trial to directly compare MST with ECT, marking an important step toward a new treatment option for patients.

Irvine, Calif., April 15, 2026 — A research team led by the University of California, Irvine’s Joe C. Wen School of Population & Public Health has uncovered a critical biological link explaining why individuals with metabolic dysfunction–associated steatotic liver disease (MASLD), or fatty liver disease, face significantly worse outcomes from certain foodborne infections.